AR054387A1 - Intermediarios utiles en la sintesis de moduladores de alquilquinolina y alquilquinazolina quinasa, y metodos de sintesis relacionados - Google Patents

Intermediarios utiles en la sintesis de moduladores de alquilquinolina y alquilquinazolina quinasa, y metodos de sintesis relacionados

Info

Publication number
AR054387A1
AR054387A1 ARP060102423A ARP060102423A AR054387A1 AR 054387 A1 AR054387 A1 AR 054387A1 AR P060102423 A ARP060102423 A AR P060102423A AR P060102423 A ARP060102423 A AR P060102423A AR 054387 A1 AR054387 A1 AR 054387A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
alkoxy
heteroaryl
halogen
Prior art date
Application number
ARP060102423A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR054387A1 publication Critical patent/AR054387A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos de la presente son utiles en la síntesis de los inhibidores de la proteína tirosinquinasa, particularmente los inhibidores de FLT3 y/o c-kit y/o TrkB. Reivindicacion 1: Un compuesto de formula (1) y N-oxidos y los isomeros estereoquímicos de éstos, donde X es N o CH; R1 y R2 están independientemente seleccionados de los restos de formulas (a-1) a (a-6) donde n es 1, 2, 3 o 4; Y es un enlace directo, O, S, NH, o N(alquilo); Ra es alcoxi, fenoxi, heteroarilo opcionalmente sustituido con R5, hidroxilo alquilamino, dialquilamino, oxazolidinonilo opcionalmente sustituido con R5, pirrolidinonilo opcionalmente sustituido con R5, piperidinonilo opcionalmente sustituido con R5, piperazinil-2-ona opcionalmente sustituido con R5, heterodionilo cíclico opcionalmente sustituido con R5, heterociclilo opcionalmente sustituido con R5, escuarilo opcionalmente sustituido con R5, -COORy, -CONRwRx, -N(Ry)CON(Rw)(Rx), -N(Rw)C(O)ORx, -N(Rw)CORy, -SRy, -SORy, -SO2Ry, - NRwSO2Ry, -NRwSO2Rx, -SO3Ry, -OSO2NRwRx, o -SO2NRwRx; Rw y Rx están independientemente seleccionados de: H, alquilo, alquenilo, aralquilo o heteroaralquilo, o Rw y Rx pueden estar tomados conjuntamente opcionalmente para formar un anillo de 5 a 7 miembros, que contiene opcionalmente una heteroporcion seleccionada de O, NH, N(alquilo), SO, SO2, o S; Ry está seleccionado de: H, alquilo, alquenilo, cicloalquilo, fenilo, aralquilo, heteroaralquilo, o heteroarilo, R5 es 1, 2 o 3 sustituyentes independientemente seleccionados de: halogeno, ciano, trifluormetilo, amino, hidroxilo, heteroarilo, alcoxi, -C(O)alquilo, -SO2alquilo, -C(O)NH(alquilo), -C(O)N(alquilo)2, -C(O)C(1-4)alquil-N(alquilo)2, alquilo, -C(1-4)alquilo-OH, -C(1-4)alquilo- OCH3, -C(O)C(1-4)alquilo-OH, -C(O)C(1-4)alquilo-OCH3, un grupo protector (donde dicho grupo protector es preferiblemente fluoren-9-il-metil-oxicarbonilo), dialquilamino, o alquilamino; con la condicion de que no esté presente el mismo sustituyente R5 más de una vez, a menos que dicho sustituyente R5 sea halogeno, hidroxilo, alcoxi, o alquilo; Rbb es H con la condicion de que ambos R1 y R2 no sean H, o Rbb es alcoxi con la condicion de que ambos R1 y R2 no sean alcoxi; o Rbb está seleccionado del grupo que consiste en: halogeno, dialquilamino, fenilo, heteroarilo, piperazinil-2-ona opcionalmente sustituido con R6, imidazolidinil-2-ona opcionalmente sustituido con R6, oxazolidinil-2-ona opcionalmente sustituido con R6, o heterociclilo opcionalmente sustituido con R6; R6 es 1, 2 o 3 sustituyentes independientemente seleccionados de: halogeno, ciano, trifluormetilo, amino, hidroxilo heteroarilo,.alcoxi, -C(O)alquilo, -SO2alquilo, -C(O)NH(alquilo), -C(O)N(alquilo)2, -C(O)C(1- 4)alquil-N(alquilo)2, alquilo, -C(1-4)alquilo-OH, -C(1-4)alquilo-OCH3, -C(O)C(1-4)alquilo-OH, -C(O)C(1-4)alquilo-OCH3, dialquilamino, o alquilamino; con la condicion de que el mismo sustituyente R6 no esté presente más de una vez, a menos que dicho sustituyente R6 sea halogeno, hidroxilo, alcoxi, o alquilo; Rc es heterociclilo opcionalmente sustituido con R7, o heteroarilo; y R7 es 1, 2 o 3 sustituyentes independientemente seleccionados de: halogeno, ciano, trifluormetilo, amino, hidroxilo, heteroarilo, alcoxi, -C(O)alquilo, -SO2alquilo, -C(O)NH(alquilo), -C(O)N(alquilo)2, -C(O)C(1-4)alquil-N(alquilo)2, alquilo, -C(1-4)alquilo-OH, -C(1-4)alquilo-OCH3, -C(O)C(1-4)alquilo-OH, -C(O)C(1-4)alquilo-OCH3, dialquilamino, o alquilamino; con la condicion de que el mismo sustituyente R7 no esté presente más de una vez, a menos que dicho sustituyente R7 sea halogeno, hidroxilo, alcoxi, o alquilo; y R99 es H, o un grupo protector.
ARP060102423A 2005-06-10 2006-06-09 Intermediarios utiles en la sintesis de moduladores de alquilquinolina y alquilquinazolina quinasa, y metodos de sintesis relacionados AR054387A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68938405P 2005-06-10 2005-06-10
US73091905P 2005-10-27 2005-10-27
US78955106P 2006-04-05 2006-04-05

Publications (1)

Publication Number Publication Date
AR054387A1 true AR054387A1 (es) 2007-06-20

Family

ID=37038264

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102423A AR054387A1 (es) 2005-06-10 2006-06-09 Intermediarios utiles en la sintesis de moduladores de alquilquinolina y alquilquinazolina quinasa, y metodos de sintesis relacionados

Country Status (20)

Country Link
US (1) US7825244B2 (es)
EP (1) EP1891040A1 (es)
JP (1) JP2008545787A (es)
KR (1) KR20080033234A (es)
AR (1) AR054387A1 (es)
AU (1) AU2006258056A1 (es)
BR (1) BRPI0612543A2 (es)
CA (1) CA2611219A1 (es)
CR (1) CR9651A (es)
EA (1) EA200800010A1 (es)
EC (1) ECSP077993A (es)
GT (1) GT200600250A (es)
IL (1) IL187688A0 (es)
MX (1) MX2007015739A (es)
NI (1) NI200700312A (es)
NO (1) NO20080160L (es)
PA (1) PA8679201A1 (es)
TW (1) TW200718694A (es)
UY (1) UY29589A1 (es)
WO (1) WO2006135646A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US8880138B2 (en) * 2005-09-30 2014-11-04 Abbott Diabetes Care Inc. Device for channeling fluid and methods of use
BR112016008080B1 (pt) * 2013-10-16 2021-02-23 Fujifilm Corporation sal de ácido carboxílico ou um sal de ácido mineral, cristal de succinato, cristal de fumarato e composição farmacêutica
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517005A (en) * 1967-10-26 1970-06-23 Pfizer & Co C Certain 2- and 4-substituted quinazolines
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
JPS5976082A (ja) 1982-10-23 1984-04-28 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
GB8320958D0 (en) * 1983-08-03 1983-09-07 Pfizer Ltd Quinazoline cardiac stimulants
US5300515A (en) * 1991-01-31 1994-04-05 Kyorin Pharmaceutical Co., Ltd. Carbamic acid derivatives and method for preparing the same
CA2131528C (en) * 1992-03-05 2004-07-13 Philip E. Thorpe Methods and compositions for targeting the vasculature of solid tumors
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
EP0822788B1 (en) 1995-04-19 2002-09-04 Schneider (Usa) Inc. Drug release coated stent
WO1998014431A1 (fr) 1996-10-01 1998-04-09 Kyowa Hakko Kogyo Co., Ltd. Composes azotes heterocycliques
WO1997028118A1 (en) 1996-02-05 1997-08-07 Hoechst Celanese Corporation Process for preparing anthranilic acids
US5948786A (en) * 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
DE69718306D1 (de) 1996-04-12 2003-02-13 Sumitomo Pharma Piperidinylpyrimidine derivate
US5866562A (en) * 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
EP1047691A1 (en) 1997-12-12 2000-11-02 Smithkline Beecham Plc Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
DE19756388A1 (de) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
JP4926320B2 (ja) * 1999-04-28 2012-05-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
AU1071301A (en) 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
EP1309569B1 (en) 2000-08-18 2010-10-06 Millennium Pharmaceuticals, Inc. N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors
EP1309567A2 (en) 2000-08-18 2003-05-14 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds
US6656942B2 (en) 2000-10-17 2003-12-02 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
JP2004520299A (ja) 2000-12-12 2004-07-08 ニューロジェン・コーポレーション スピロ［イソベンゾフラン−１，４’−ピペリジン］−３−オン類及び３ｈ−スピロイソベンゾフラン−１，４’−ピペリジン類
DE10109866A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
WO2002088107A1 (en) 2001-04-26 2002-11-07 Eisai Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
KR20090087139A (ko) 2001-10-30 2009-08-14 노파르티스 아게 Ｆｌｔ３ 수용체 티로신 키나아제 활성의 억제제로서의 스타우로스포린 유도체
AU2002360753B2 (en) 2001-12-27 2008-08-21 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
KR101093345B1 (ko) 2002-02-01 2011-12-14 아스트라제네카 아베 퀴나졸린 화합물
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CN1678586A (zh) 2002-06-27 2005-10-05 舍林股份公司 取代的喹啉ccr5受体拮抗剂
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
WO2004016597A2 (en) 2002-08-14 2004-02-26 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
EP1566379A4 (en) 2002-10-29 2005-11-09 Kirin Brewery QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME
JP2006511616A (ja) 2002-11-13 2006-04-06 カイロン コーポレイション 癌の処置方法およびその関連方法
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
US7226919B2 (en) 2002-12-18 2007-06-05 Vertex Pharmaceuticals Inc. Compositions useful as inhibitors of protein kinases
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
JP4845736B2 (ja) 2003-10-14 2011-12-28 アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ プロテインキナーゼ阻害剤
NZ547327A (en) 2003-11-21 2009-08-28 Array Biopharma Inc AKT protein kinase inhibitors
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) * 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators

Also Published As

Publication number Publication date
WO2006135646A1 (en) 2006-12-21
CA2611219A1 (en) 2006-12-21
IL187688A0 (en) 2008-08-07
NI200700312A (es) 2009-02-19
NO20080160L (no) 2008-01-09
US7825244B2 (en) 2010-11-02
KR20080033234A (ko) 2008-04-16
AU2006258056A1 (en) 2006-12-21
US20070021436A1 (en) 2007-01-25
EP1891040A1 (en) 2008-02-27
JP2008545787A (ja) 2008-12-18
PA8679201A1 (es) 2007-01-17
ECSP077993A (es) 2008-01-23
EA200800010A1 (ru) 2008-06-30
CR9651A (es) 2008-09-09
BRPI0612543A2 (pt) 2010-11-23
UY29589A1 (es) 2006-10-02
TW200718694A (en) 2007-05-16
MX2007015739A (es) 2008-04-29
GT200600250A (es) 2007-03-14

Similar Documents

Publication Publication Date Title
AR057062A1 (es) Moduladores de aminoquinolina y aminoquinazolina quinasa
AR049951A1 (es) Derivados de ftalazina como inhibidores de parp
AR054387A1 (es) Intermediarios utiles en la sintesis de moduladores de alquilquinolina y alquilquinazolina quinasa, y metodos de sintesis relacionados
AR040412A1 (es) Derivados de sulfamato sustituido como anticonvulsivo
AR054386A1 (es) Moduladores de quinasas con estructuras de alquiloquinolina y alquilquinazolina
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
AR076067A1 (es) Composiciones y metodos para modular la senda de senalizacion de wnt
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
AR049739A1 (es) Derivados de aril-piridina
AR057705A1 (es) 3-acilaminobenzanilidas insecticidas
CR8468A (es) Derivado de n-(1,5-difenil-1h-pirazol-3-il)metil)sulfonamida con afinidad por los receptores cb1
MY161631A (en) Herbicidal pyrimidone derivatives
PE20181304A1 (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
AR065249A1 (es) Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales.
AR044629A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
AR053895A1 (es) Aminopirimidinas como moduladores de quinasas
AR057063A1 (es) Moduladores de tienopirimidina y tienopiridina quinasa y composicion farmaceutica
SG155946A1 (en) Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
PE20211265A1 (es) Herbicidas de piridazinona novedosos
AR053141A1 (es) Imidazoles sustituidos con heterociclilamida
AR111672A1 (es) Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
AR008287A1 (es) Composicion herbicida que comprende compuestos de pirazol sustituidos y metodo de aplicacion de los mismos
AR102825A1 (es) Derivados heterocíclicos de amida activos como plaguicidas con sustituyentes que contienen azufre
AR115495A1 (es) Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal